WS Investor
24 Sep 2026, 19:35
United Therapeutics Falls as Goldman Sachs Starts Coverage With Sell Rating
United Therapeutics (NASDAQ: UTHR) shares fell about 4.1% after Goldman Sachs initiated coverage of the biotechnology company with a Sell rating and a $321 price target.
Analyst Andrea Newkirk’s cautious view reflects concerns about valuation and the company’s longer-term growth outlook. Goldman noted that United Therapeutics trades at roughly 17–18 times earnings, above its 10-year median of about 13 times, despite pressure on its existing business. The firm also sees the commercial opportunity for nebulized Tyvaso in idiopathic pulmonary fibrosis as more challenging than the market expects, citing dosing frequency and tolerability as potential constraints on patient uptake and adherence. Goldman forecasts peak Tyvaso IPF sales below consensus expectations and also sees execution risks around the future Jenraldi launch in pulmonary arterial hypertension (Investing*com)
United Therapeutics shares were trading around $469.47, down roughly 4.1%. Goldman Sachs’ $321 target sits well below the current share price.
United Therapeutics (NASDAQ: UTHR) shares fell about 4.1% after Goldman Sachs initiated coverage of the biotechnology company with a Sell rating and a $321 price target.
Analyst Andrea Newkirk’s cautious view reflects concerns about valuation and the company’s longer-term growth outlook. Goldman noted that United Therapeutics trades at roughly 17–18 times earnings, above its 10-year median of about 13 times, despite pressure on its existing business. The firm also sees the commercial opportunity for nebulized Tyvaso in idiopathic pulmonary fibrosis as more challenging than the market expects, citing dosing frequency and tolerability as potential constraints on patient uptake and adherence. Goldman forecasts peak Tyvaso IPF sales below consensus expectations and also sees execution risks around the future Jenraldi launch in pulmonary arterial hypertension (Investing*com)
United Therapeutics shares were trading around $469.47, down roughly 4.1%. Goldman Sachs’ $321 target sits well below the current share price.
